Abstracts Archive - Page 1858 of 2425 - ACR Meeting Abstracts

Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Jérémie Sellam¹, Houria Chavez², Stéphanie Rouanet³, Nathalie Vernet³, Bineta Ly⁴, Sandrine Marion-Thore⁵, Bernard Combe⁶, Jean Sibilia⁷, Jacques Tebib⁸, Gilles Chiocchia⁹, Maxime Dougados¹⁰, Yassine Taoufik² and Xavier Mariette¹¹, ¹AP-HP, Saint-Antoine Hospital, Rheumatology Department and DHU i2B, Paris, France, ²Biologic Immunology, Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, ³Biostatistics, Roche France, Boulogne-Billancourt, France, ⁴INSERM U1012, Universite Paris-Sud, Kremlin Bicetre, France, ⁵INSERM U1016, Université Versailles Saint-Quentin, Montigny le Bretonneux, France, ⁶Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸Rheumatology, University Hospital Lyon, Lyon, France, ⁹Université Versailles-Saint Quentin, Montigny le Bretonneux, France, ¹⁰INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ¹¹rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, France
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…
Abstract Number: 2929 • 2014 ACR/ARHP Annual Meeting
Molecular Diagnostics for Patient Subsetting in Sjögren’s Syndrome
John C. Hall¹, Alan N. Baer¹, Mi Y. Lam², Lindsey A. Criswell³, Antony Rosen¹ and Livia Casciola Rosen¹, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Orofacial Sciences, University of California San Francisco, San Francisco, CA, ³Medicine, University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA
Background/Purpose Sjögren’s syndrome (SS) is a chronic autoimmune disease which targets exocrine glands, particularly salivary and lacrimal glands. While all SS patients have abnormal secretory…
Abstract Number: 2930 • 2014 ACR/ARHP Annual Meeting
Precisely Quantified Fibrosis in Labial Salivary Glands Predicts Sjögren’s Syndrome Classification in a Multiple Regression Model
Kerry M. Leehan^1,2, Michael Brown¹, Courtney Montgomery¹, Astrid Rasmussen¹, David M. Lewis³, Lida Radfar⁴, Donald U. Stone⁵, Stephen Young³, R. Hal Scofield^1,6, Kathy L. Sivils^1,2 and A. Darise Farris^2,7, ¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴College of Dentristry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Department of Ophthalmology, Dean McGee Eye Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Department of Endocrinology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁷Arthritis and Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Primary Sjögren's Syndrome (pSS) is a systemic, progressive autoimmune exocrinopathy that presents diagnostic challenges. Focal lymphocytic infiltrates in labial salivary gland (SG) biopsies, serum…
Abstract Number: 2931 • 2014 ACR/ARHP Annual Meeting
Longitudinal Examination with Salivary Gland Ultrasonography (SGUS) of Patients with Primary Sjogren’s Syndrome: A Single Center Experience
Chiara Baldini¹, Nicoletta Luciano¹, Francesca Sernissi¹, Daniela Martini¹, Francesco Ferro¹, Marta Mosca² and Stefano Bombardieri², ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Recently, convincing data have been published on the diagnostic value of salivary gland ultrasonography (SGUS) in primary Sjögren’s syndrome (pSS). However, a limited number…
Abstract Number: 2932 • 2014 ACR/ARHP Annual Meeting
Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren’s Syndrome: A General Population-Based Cohort Study
Marko Yurkovich¹, Hyon K. Choi², Eric C. Sayre³, Kamran Shojania⁴ and J. Antonio Avina-Zubieta⁵, ¹Department of Medicine, University of British Columbia, Vancouver, BC, Canada, ²Boston University School of Medicine, Boston, MA, ³Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Rheumatology, University of British Columbia, Vancouver, BC, Canada, ⁵Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada
Background/Purpose: There is limited data available on the risk of deep venous thrombosis (DVT) and pulmonary embolism (PE) in Sjögren's Syndrome (SjS). We estimated the…
Abstract Number: 2933 • 2014 ACR/ARHP Annual Meeting
Metabolic Syndrome, Adipocytokines and Inflammation in Sjögren’s Syndrome
Kristopherson Lustosa Augusto¹, Eloisa Bonfá², Rosa M. R. Pereira¹, Cleonice Bueno³, Vilma S. T. Viana⁴ and Sandra G. Pasoto⁵, ¹Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ²Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ³Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
Background/Purpose Systemic inflammation has been linked to increased frequency of metabolic syndrome (MetS) in autoimmune diseases. However, there are no studies concerning the frequency of…
Abstract Number: 2934 • 2014 ACR/ARHP Annual Meeting
Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjögren’s Syndrome
Gwenny Verstappen¹, Wayel H. Abdulahad², Petra M. Meiners³, Suzanne Arends⁴, Silvia Beijer-Liefers⁵, Arjan Vissink³, Frans G.M. Kroese⁴ and Hendrika Bootsma⁴, ¹Rheumatology & Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ³Oral and Maxillofacial Surgery, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁴Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose In an open-label proof of concept study, Abatacept has been identified as an effective and safe treatment modality in primary Sjögren’s syndrome (pSS). Abatacept…
Abstract Number: 2935 • 2014 ACR/ARHP Annual Meeting
Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis
Barry J. Sheane¹, Arane Thavaneswaran², Dafna D. Gladman² and Vinod Chandran², ¹Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose Methotrexate (MTX) is used as first-line treatment in psoriatic arthritis (PsA); however, the extent of the disease-modifying effect of MTX on PsA, if any,…
Abstract Number: 2895 • 2014 ACR/ARHP Annual Meeting
Habitual Running Any Time in Life Is Not Detrimental and May be Protective of Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Grace H. Lo¹, Jeffrey B. Driban², Andrea Kriska³, Kristi Storti³, Timothy E. McAlindon⁴, Richard Souza⁵, Charles B. Eaton⁶, Nancy J. Petersen⁷ and Maria E. Suarez-Almazor⁸, ¹VA HSR&D Center for Innovations in Quality, Effectiveness and Safety; Medical Care Line and Research Care Line; Department of Medicine, Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, ²Tufts Medical Center, Boston, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Division of Rheumatology, Tufts Medical Center, Boston, MA, ⁵University of California, San Francisco, San Francisco, CA, ⁶Family Medicine, Memorial Hospital of Rhode Island, Pawtucket, RI, ⁷Medicine, Baylor College of Medicine, Houston, TX, ⁸The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose Controversy exists regarding whether habitual running is beneficial versus harmful to the knee. Chronic mechanical overloading could potentially physically damage structures within the knee. …
Abstract Number: 2896 • 2014 ACR/ARHP Annual Meeting
a Multi-Center Double-Blind, Randomized, Controlled Trial (db-RCT) to Evaluate the Effectiveness and Safety of Co-Administered Traumeel^® (Tr14) and Zeel^® (Ze14) Intra‑articular (IA) Injections Versus IA Placebo in Patients with Moderate-to-Severe Pain Associated with OA of the Knee
Carlos Lozada¹, Eve del Rio², Donald Reitberg², Robert Smith², Charles Kahn³ and Roland W. Moskowitz⁴, ¹Rheumatology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL, ²Clinical Research, Rio Pharmaceutical Services, LLC, Bridgewater, NJ, ³South Florida Rheumatology, Hollywood, FL, ⁴Div of Rheum/Dept of Medicine, University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: Tr14 & Ze14 is a combination of dilute biological and mineral extracts administered IA for painful knee OA. In response to clinician impressions of…
Abstract Number: 2897 • 2014 ACR/ARHP Annual Meeting
Exercise Therapy and/or Manual Therapy for Hip or Knee Osteoarthritis: 2-Year Follow-up of a Randomized Controlled Trial
J. Haxby Abbott¹, Cathy Chapple², Daniel Pinto³, Alexis Wright⁴ and Jean-Claude Theis⁵, ¹Centre for Musculoskeletal Outcomes Research, Department of Surgical Sciences, University of Otago, Dunedin, New Zealand, ²School of Physiotherapy, University of Otago, Dunedin, New Zealand, ³Department of Physical Therapy & Human Movement Sciences, Northwestern University, Chicago, IL, ⁴Department of Physical Therapy, High Point University, High Point, NC, ⁵Centre for Musculoskeletal Outcomes Research, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand
Background/Purpose: Although both exercise therapy and manual therapy have evidence supporting their effectiveness in people with hip and knee osteoarthritis (OA), few clinical trials have…
Abstract Number: 2898 • 2014 ACR/ARHP Annual Meeting
New Insights into the Primary Care Osteoarthritis Consultation with Implications for Practice
Zoe Paskins¹, Tom Sanders¹, Peter Croft¹ and Andrew Hassell², ¹Research Institute for Primary Care and Health Sciences, Keele University, Keele, United Kingdom, ²School of Medicine, Keele University, Keele, United Kingdom
Background/Purpose Osteoarthritis (OA) is the commonest long term condition in primary care. Existing international guidance suggests that much can be done to improve patient outcomes…
Abstract Number: 2899 • 2014 ACR/ARHP Annual Meeting
High Dose Aspirin for Treating Kawasaki Disease – Outdated Myth or Effective Aid?
Gil Amarilyo¹, Yael Koren², Dafna Brik Simon³, Maskit Bar-Meir⁴, Hilla Bahat⁵, Mona Hanna Helou⁶, Amir Mendelson⁷, Yackov Berkun⁸, Eli Eisenstein⁹, Yonatan butbul Aviel¹⁰, Galia Barkai¹¹, Yoav Bolkier¹¹, Shai Padeh¹¹, Philip J. Hashkes¹², Riva Brik¹⁰, Liora Harel¹ and Yosef Uziel¹³, ¹Pediatric Rheumatology Unit, Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Schneider Children's Medical Center of Israel, Petach Tikvah, Israel, ⁴Infectious Diseases, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatrics, Assaf Harofeh Medical Center, Zerifin, Israel, ⁶Pediatrics B Department, Rambam Medical Center, Haifa, Israel, ⁷Pediatric Rheumatology, Meir Medical Center, Kfar Saba, Israel, ⁸Pediatrics and Pediatric Rheumatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ⁹Dept of Pediatrics, Hadassah Hebrew University Medical Center, Jerusalem, Israel, ¹⁰Pediatric Rheumatology, Rambam Medical Center, Haifa, Israel, ¹¹Sheba Medical Center, Tel-Hashomer, Israel, ¹²Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ¹³Pediatric Rheumatology Unit , Department of Pediatrics, Meir Medical Center, Kfar Saba, Israel
Background/Purpose: Kawasaki disease (KD) is generally treated with intravenous immunoglobulin (IVIG) together with high anti-inflammatory doses of acetyl salicylic acid (ASA), which is subsequently switched…
Abstract Number: 2900 • 2014 ACR/ARHP Annual Meeting
Clinically Inactive Disease in Juvenile Dermatomyositis – a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria
Beverley Almeida¹, Raquel Campanilho-Marques², Katie Arnold², Lucy R. Wedderburn^3,4, Clarissa A Pilkington⁵ and Kiran Nistala⁶, ¹Department of Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ²Infection, Inflammation and Rheumatology Section, UCL Institute for Child Health, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Arthritis Research UK Centre for Adolescent Rheumatology,, UCL, UCLH, GOSH NHS Trust, London, United Kingdom, ⁵Rheumatology, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, ⁶Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Juvenile dermatomyositis (JDM) affects 3 children/million/year with myositis and skin disease being the typical features. The Pediatric Rheumatology International Trials Organisation (PRINTO) have recently…
Abstract Number: 2901 • 2014 ACR/ARHP Annual Meeting
Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis
Gabriele Simonini¹, Claudia Bracaglia², Marco Cattalini³, Andrea Taddio⁴, Alice Brambilla⁵, Cinzia DeLibero⁶, Denise Pires Marafon⁷, Roberto Caputo⁶ and Rolando Cimaz¹, ¹Pediatric Rheumatology, Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ²Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ³Pediatric Clinic, Spedali Civili di Brescia and University of Brescia, Pediatric Immunology and Rheumatology Unit, Brescia, Italy, ⁴Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy, ⁵Anna Meyer Children's Hospital-University of Firenze, Florence, Italy, ⁶Ophthalmology Unit, Anna Meyer Children's Hospital, Florence, Italy, ⁷Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy
Background/Purpose Information regarding the natural clinical history of a child on systemic treatment due to auto-immune chronic uveitis would be helpful in driving duration therapy.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].